Related Experiment Video
Updated: Jun 28, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Does estrogen receptor gene polymorphism play a role in Parkinson's disease?
Xue-Li Li1, Wei-Dong Cheng, Juan Li
1Department of Neurology, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong Province 252000, PR China. lixueli2001@yahoo.com.cn
Abstract:
This study was designed to investigate the frequency of estrogen receptor (ER) gene polymorphism in Chinese patients with Parkinson's disease (PD). Polymerase chain reaction (PCR) method and restriction fragment length polymorphism (RFLP) were used to detect the ER gene polymorphisms in 158 PD patients and 146 healthy controls. In the PD and control groups, "x" accounted for 83.5% and 80.8%, respectively (P>0.05). "xx" was found in 77.2% of the PD group and in 69.9% of the control group (P>0.05). The frequency of "p" in the PD and control group was 67.7% and 64.0%, respectively (P>0.05). "pp" was 51.9% in the PD group and 43.8% in the control group (P>0.05). "ppxx" was found in 49.4% of the PD and 43.0% of the control subjects (P>0.05). There was no significant difference in the "x", "xx", "p", "pp" or "ppxx" between males and females within the PD or control groups. In conclusion, we found no significant differences in the genotype or allele frequencies between patients with Parkinson's disease and healthy subjects. These findings suggest that the estrogen receptor gene polymorphism may not play a key role in the pathogenesis PD in Chinese patients.
Related Concept Videos
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Neural Regulation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
